26
ALL1
Arrowhead Pharmaceuticals1
Assembly Biosciences19
Gilead Sciences3
Lupin Ltd2
ViiV HealthcareYear
26
ALL5
20244
202310
20224
20213
2020DEALS // DEV.
26
ALL2
Deals24
DevelopmentsCountry
26
ALL3
INDIA21
U.S.A2
UNITED KINGDOM26
ALL1
CHAI1
Gilead Sciences1
Johnson & Johnson Innovative Medicine23
Not ApplicableTherapeutic Area
26
ALL25
Infections and Infectious Diseases1
TechnologyStudy Phase
26
ALL22
Approved1
Phase III1
Phase II/ Phase III2
Phase IIDeal Type
2
ALL1
Licensing Agreement1
PartnershipProduct Type
26
ALL1
Large molecule25
Small moleculeDosage Form
23
ALL1
Oral1
Subcutaneous Injection16
Tablet5
Tablet, Film CoatedLead Product
26
ALL15
Bictegravir1
Dolutegravir Sodium3
Emtricitabine1
JNJ-737639891
Lenacapavir4
Tenofovir Alafenamide1
VebicorvirTarget
16
ALL1
Core protein allosteric2
DNA polymerase1
HBsAg1
HIV-1 capsid7
HIV-1 integrase2
HIV-1 integrase strand transfer1
HIV-1 integrase strand transfer1
HIV-1 reverse transcriptaseLead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin receives US FDA tentative marketing approval for generic Descovy tablets
Details : Emtricitabine & tenofovir alafenamide is a generic equivalent of Descovy. This combination is NRT-inhibitor. It is indicated for HIV-1 Infection in adults & pediatric patients.
Brand Name : Descovy-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2024
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is now approved for the treatment of HIV in pregnant adults.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Expands Gilead's Vemlidy Indication To Treat Chronic HBV in Pediatric Patients
Details : Vemlidy (tenofovir alafenamide) is approved for chronic hepatitis B in pediatric patients (6+ years) with compensated liver disease.
Brand Name : Vemlidy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2024
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biktarvy® Shows High Rates of Viral Suppression in HIV Patients with Comorbidities
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is being evaluated for the treatment of HIV and Hepatitis B.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Expanded Indication for Biktarvy to Treat HIV with Suppressed Viral Loads
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It got extended approval for HIV with suppressed viral loads, pre-existing resistance.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : CHAI
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to accelerate the development of an investigational dispersible pediatric formulation containing Descovy (emtricitabine) and tenofovir alafenamide (F/TAF).
Brand Name : Descovy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : CHAI
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Approval from USFDA for Tenofovir Alafenamide Tablets
Details : Tenofovir alafenamide accumulates more in peripheral blood mononuclear cells compared to red blood cells. Once activated, it acts with different mechanisms including the inhibition of viral polymerase, causing chain termination and the inhibition of vira...
Brand Name : Vemlidy-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2023
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy is a combination of bictegravir which targets HIV-1 integrase thus inhibiting HIV virus replication, emtricitabine and tenofovir alafenamide which inhibits the activity of the HIV-1 reverse transcriptase resulting in DNA chain termination.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The combination inhibits HIV-1 replication, in which dolutegravir inhibits HIV integrase and blocks the strand transfer step of retroviral DNA integration where emtricitabine and tenofovir alafenamide inhibits the activity of the HIV-1 reverse transcript...
Brand Name : Dolutegravir/Emtricitabine/Tenofovir Alafenamide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2023
Lead Product(s) : Dolutegravir Sodium,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?